37519-04-3Relevant articles and documents
Synthesis of highly-functionalised pyridines via hetero-Diels-Alder methodology: reaction of 3-siloxy-1-aza-1,3-butadienes with electron deficient acetylenes
Fletcher, Matthew D.,Hurst, Timothy E.,Miles, Timothy J.,Moody, Christopher J.
, p. 5454 - 5463 (2006)
The hetero-Diels-Alder reaction between 1-aza-3-siloxy-1,3-butadienes and electron deficient acetylenes is described. The reactivity of a range of α,β-unsaturated oximes and hydrazones is assessed in the synthesis of tri- and tetra-substituted pyridines b
CYCLIC PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
-
Page/Page column 30; 31, (2015/03/28)
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
NG-aminoguanidines from primary amines and the preparation of nitric oxide synthase inhibitors
Martin, Nathaniel I.,Beeson, William T.,Woodward, Joshua J.,Marletta, Michael A.
, p. 924 - 931 (2008/09/20)
A concise, general, and high-yielding method for the preparation of N G-aminoguanidines from primary amines is reported. Using available and readily prepared materials, primary amines are converted to protected N G-aminoguanidines in a one-pot procedure. The method has been successfully applied to a number of examples including the syntheses of four nitric oxide synthase (NOS) inhibitors. The inhibitors prepared were investigated as competitive inhibitors and as mechanistic inactivators of the inducible isoform of NOS (iNOS). In addition, one of the four inhibitors prepared, NG-amino-NG-2,2,2-trifluoroethyl-L-arginine 19, displays the unique ability to both inhibit NO formation and prevent NADPH consumption by iNOS without irreversible inactivation of the enzyme.